{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-009264","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.968991+00:00","generated_at":"2026-06-06T22:29:55.153135+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myomo reports prelim Q4 revenue $4.6-$4.8M (+14-19% YoY), raises $6M in registered direct offering","bullets":["Preliminary Q4 2023 revenue expected $4.6-$4.8M, up 14-19% YoY; cash $8.7M at Dec 31, 2023.","Backlog of ~230 patients as of Dec 31, 2023, up ~40% YoY; CMS classified MyoPro as a brace, reimbursed lump sum.","Raised $6M gross via registered direct offering of 1.58M shares/pre-funded warrants at $3.80, priced at market.","Proceeds to scale up for Medicare Part B, hire ~50 people; expects cash flow breakeven by Q4 2024.","CEO targets $100M annual revenue within five years; offering includes insiders and institutional investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-009264","json":"https://secwatch.observer/filing/0001193125-24-009264.json","markdown":"https://secwatch.observer/filing/0001193125-24-009264.md","text":"https://secwatch.observer/filing/0001193125-24-009264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/0001193125-24-009264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/d573347d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:29:55.153135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c30a681a1635e8945e1e9e172722d2b24dbc9a5","claim":"MYOMO, INC. reported the fourth quarter of 2023 results: revenue in the range of $4.6 million to $4.8 million.","evidence_excerpt":"Revenue for the fourth quarter of 2023 is expected to be in the range of $4.6 million to $4.8 million, an increase of 14% to 19%, compared with the same period a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/0001193125-24-009264-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"in the range of $4.6 million to $4.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"fb5f8aeceb391085a984d7521783057f8df405a1","claim":"MYOMO, INC. entered into Purchase Agreement with certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company valued at gross proceeds of $6 million (effective 2024-01-16).","evidence_excerpt":"On January 16, 2024, Myomo, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) (i) 1,354,218 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (each a “Share” and collectively the “Shares”); and (ii) pre-funded warrants in lieu of shares of Common Stock (the “Pre-Funded Warrants”) to purchase 224,730 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/0001193125-24-009264-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company"},{"label":"Value","value":"gross proceeds of $6 million"},{"label":"Effective","value":"2024-01-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}